






# Geography Management



陈斌



THE UNIVERSITY OF  
THE SOUTH CHINA SEAS  
FACULTY OF  
LAW AND POLITICAL SCIENCE  
SCHOOL OF  
POLITICAL SCIENCE AND  
ADMINISTRATION

UNIVERSITY OF THE SOUTH CHINA SEAS

# Abstract

## The 2016 Corporate Social Responsibility (CSR) Report of China Tobacco Company Limited

The 2016 CSR Report of China Tobacco Company Limited (China Tobacco) is the first report published by the company in accordance with the GB/T 36000-2015 standard. It is a comprehensive report that covers the company's performance in various areas of CSR, including environment, employees, customers, society, and philanthropy.

The report is structured according to the GB/T 36000-2015 standard, which is based on the GRI (Global Reporting Initiative) standards. It is divided into four main sections: Environment, Employees, Customers, and Society. Each section contains detailed information about the company's activities, achievements, and challenges in that area.

Reporting Period: January 1, 2016 to December 31, 2016

Reporting Unit: China Tobacco Company Limited  
 Reporting Language: Chinese  
 Reporting Currency: RMB (Renminbi)  
 Reporting Period: January 1, 2016 to December 31, 2016

The report is published in Chinese and English. The Chinese version is the primary version, and the English version is a translation of the Chinese version. The report is available on the company's website and in print form.

The report is a comprehensive document that provides a detailed overview of the company's CSR performance. It is a valuable resource for stakeholders, including investors, customers, employees, and the general public. The report is a reflection of the company's commitment to social responsibility and its efforts to create a sustainable future.

The report is a comprehensive document that provides a detailed overview of the company's CSR performance. It is a valuable resource for stakeholders, including investors, customers, employees, and the general public. The report is a reflection of the company's commitment to social responsibility and its efforts to create a sustainable future.

The report is a comprehensive document that provides a detailed overview of the company's CSR performance. It is a valuable resource for stakeholders, including investors, customers, employees, and the general public. The report is a reflection of the company's commitment to social responsibility and its efforts to create a sustainable future.

The report is a comprehensive document that provides a detailed overview of the company's CSR performance. It is a valuable resource for stakeholders, including investors, customers, employees, and the general public. The report is a reflection of the company's commitment to social responsibility and its efforts to create a sustainable future.



The 2016 CSR Report of China Tobacco Company Limited is a comprehensive document that provides a detailed overview of the company's CSR performance. It is a valuable resource for stakeholders, including investors, customers, employees, and the general public. The report is a reflection of the company's commitment to social responsibility and its efforts to create a sustainable future.

The 2016 CSR Report of China Tobacco Company Limited is a comprehensive document that provides a detailed overview of the company's CSR performance. It is a valuable resource for stakeholders, including investors, customers, employees, and the general public. The report is a reflection of the company's commitment to social responsibility and its efforts to create a sustainable future.

# CONTENTS

04 A R

14 A



42 H



90 C



112 P

115 F

116 T

121 T

06 H 2016

32 E



56 I



102 C



122 G O C S R  
P (GB36002)

131 G R G4I

140 A S SGS

# Highlights of 2016

July

August

September

In July, we announced that we had received FDA approval for our first generic product, a 30-day supply of 86% of the active ingredient in the generic product. This is a significant milestone for our company as it demonstrates our commitment to providing high-quality, affordable healthcare solutions to our patients.

In August, we announced that we had received FDA approval for our first generic product, a 30-day supply of 86% of the active ingredient in the generic product. This is a significant milestone for our company as it demonstrates our commitment to providing high-quality, affordable healthcare solutions to our patients.

In September, we announced that we had received FDA approval for our first generic product, a 30-day supply of 86% of the active ingredient in the generic product. This is a significant milestone for our company as it demonstrates our commitment to providing high-quality, affordable healthcare solutions to our patients.




# Rewards and Recognitions



## Leading Ranking Category

- July • **Top 100 Pharmaceutical Industry Enterprises of China**  
China National Pharmaceutical Industry Information Center of Ministry of Industry and Information
- September • **Ranked 3rd among the Top 100 Strengths of Pharmaceutical Research and Development in China, ranked 2nd among the Strengths of Biopharmaceutical Research and Development in China**  
YAOZH.COM
- November • **Ranked 14th among the Top 100 Companies in China Pharmaceutical Industry**  
CFDA South Medicine Economic Research Institute, Medicine Economic News
- November • **Top Ten Pharmaceutical Industry Enterprise Group of China**  
China Pharmaceutical Industry Association, China Association of Pharmaceutical Commerce
- November • **Top 100 Future Enterprises in China**  
ACCA (The Association of Chartered Certified Accountants)
- November • **Most Innovative Multinational Companies**  
Bioclub



## Major Awards & Recognitions

- January

**Best Investor Relations Award**  
Awarding Institution: China Financial Market Financial Magazine
- June

**The Best Overseas Medical Investment Enterprises**  
Awarding Institution: China Chamber of Commerce for Import and Export of Medicines and Health Products
- October

**Top 20 Most Competitive Listed Pharmaceutical Companies in China, Top 10 Listed Pharmaceutical Companies with the Highest Investment Value**  
Awarding Institution: China Pharmaceutical Enterprise Management Association
- November

**Best Listed Companies in Pharmaceutical Industry**  
Awarding Institution: Value Line, China Economic Net, China reform Daily

## Corporate Social Responsibility Awards & Recognitions

- January

**The Best Social Responsibility Brand**  
Awarding Institution: Media of the Fifth Charity Festival
- July

**“Responsibility Innovation Best Case Award for the Year”**  
Awarding Institution: Jiefang Daily (Shanghai Observer), Shanghai Daily, etc.
- December

**“Corporate Social Responsibility of Listed Companies”, ranked 2nd in CSR Development Index and ranked 1st in Report Appraisal Results**  
Awarding Institution: SSRB, Shanghai Stock Exchange, Xinhuanet, Shanghai Association of Listed Companies, etc.
- December

**Golden Bee Excellent CSR Report 2016 • Leading Enterprise Award**  
Awarding Institution: MOC China WTO Tribune



M









# 为爱飞

## 向上海市福利











# Combating Childhood Malnutrition Global Resource

Learn more about our commitment to global health and nutrition at [www.pfizer.com/globalhealth](#).  
For more information, contact [pfizer@globalhealth.com](#).



A :T C

A :T C  
A M I D CSRC, G M  
S E I D L C SSE, G A S  
R E I D D C M R A S  
M I S E A I R M E A R I  
D C S R S A R I C

# Lea C Pac ce

## C... e e f... e

F... P... G  
... T... G  
... G  
S... H... K...

## C... l... e e a f... e a c...

T... G  
...  
T... G  
... 2015, G... O  
... C...  
... G... C...

## Leadership and Governance

In 2016, F. P. R. G. A. C. F. P. OA  
.42  
A. C. S. D. 23  
C.

## Accountability and Ethics

In 2016, G  
T. G  
T

## Digital Affairs

"I +", F. P. IT  
F. P. "F. P. "S. B. P.",  
I. S. M.  
G. 2016.

## The Corporate and Life Safety

T. F.

# Ma e a A a

F P  
 I 2016, F P  
 (CSR )  
 C ( )  
 ,EHS, ) (“ C “ ””),  
 C  
 M CSR F P 2016

**Ide ca f e**

S C 30

**F a f e ba**

**L e e a de cra ge**

C 200

**A e e a da a f e**

**Sc ee ga d a e e**


E

**Sc ee g f a e a e**

**A a a d c a a**

C

**Re d g a e a e**




- |     |       |      |      |
|-----|-------|------|------|
| 1 P | 9 A C | 17 C | 25 C |
| 2 R | 10 I  | 18 C | 26 C |
| 3 O | 11 Q  | 19 G | 27 T |
| 4 Q | 12 T  | 20 G | 28 A |
| 5 S | 13 P  | 21 C | 29 I |
| 6 R | 14 I  | 22 R | 30 C |
| 7 C | 15 H  | 23 P | 31 C |
| 8 C | 16 M  | 24   | 32 D |

## Safer de C...

F... P... G... CSR... G... E...  
 F... P... G... CSR... G... 2016, F... P...  
 I... J... 2016, 12... F... C... S... R... C... TOT...  
 M... C... PRC... "G... B... 2030 S... R... A..."  
 P... C... S... G... C... C... S... P... G... I... (C...), D... P... C...

## Pa... a... g... ref... a... f... "CSR G... de... e... f... Pra... ace... ca... E... e... e... C... a"

O... 10 M... C... P... E... A... C... P... I... A... C...  
 A... M... D... C... P... C... A... C... A...  
 T... C... M... C... N... P... M... A...  
 "CSR P... G... P... E... C... B... T... CSR...  
 F... P... "CSR P... G... P... E... C... 3 A... F...  
 P... CSR... C... EHS... F... P... F... P... F...  
 CSR...












## CSR Ma... age... e...

F... P... G... G... CSR... CSR...  
**CSR P...**  
 F... P... G... T... G...  
 G... F... P... G...

CSR Model - P



# S a e r d e

S i	E i t l F P i	R e f P i
 <p>S i</p>	<ul style="list-style-type: none"> <li>• S i</li> <li>• P</li> <li>• O</li> </ul>	<ul style="list-style-type: none"> <li>• I</li> <li>• T</li> <li>• E</li> <li>• C</li> </ul>
 <p>C</p>	<ul style="list-style-type: none"> <li>• P</li> <li>• P</li> <li>• P</li> </ul>	<ul style="list-style-type: none"> <li>• P</li> <li>• M</li> <li>• C</li> <li>• E</li> <li>• E</li> <li>• P</li> </ul>
 <p>M i /</p>	<ul style="list-style-type: none"> <li>• M</li> <li>• S</li> </ul>	<ul style="list-style-type: none"> <li>• E</li> <li>• C</li> <li>• E</li> <li>• T</li> </ul>
 <p>E</p>	<ul style="list-style-type: none"> <li>• P</li> <li>• P</li> <li>• C</li> </ul>	<ul style="list-style-type: none"> <li>• E</li> <li>• E</li> <li>• E</li> <li>• O</li> <li>• S</li> <li>• S</li> </ul>
 <p>S</p>	<ul style="list-style-type: none"> <li>• A</li> <li>• J</li> </ul>	<ul style="list-style-type: none"> <li>• E</li> <li>• C</li> <li>• G</li> </ul>
 <p>G</p>	<ul style="list-style-type: none"> <li>• F</li> <li>• L</li> <li>• F</li> </ul>	<ul style="list-style-type: none"> <li>• O</li> <li>• C</li> <li>• P</li> <li>• A</li> <li>• P</li> </ul>
 <p>C</p>	<ul style="list-style-type: none"> <li>• C</li> <li>• S</li> <li>• C</li> </ul>	<ul style="list-style-type: none"> <li>• A</li> <li>• P</li> <li>• A</li> </ul>
 <p>P /</p>	<ul style="list-style-type: none"> <li>• T</li> <li>• C</li> </ul>	<ul style="list-style-type: none"> <li>• O</li> <li>• C</li> </ul>
 <p>P</p>	<ul style="list-style-type: none"> <li>• F</li> <li>• S</li> </ul>	<ul style="list-style-type: none"> <li>• C</li> <li>• C</li> <li>• P</li> </ul>

# S a e n d e E g a g e e

## S r a e n d e ( l . e . )

I  
T I R I C D D F P  
E- S S E . M I R

## S...e

I 2016, F... P... "P... B... S... P...  
T... M... S... F... P... (G...)C...L... "T... L...  
P... M... A... I... S... F... P... (G...)C...L...";  
T...

F... P...  
...

A... F... P... G...

## Pee...e ac

F... P... I 2016, F... P...

I J... F... P... CIMC, M... G...  
2016 A... M... C... E... A... F... A...;

I S... F... P... C... C...  
B... I N... A...;

I O... F... P... "2016 F... P... B... I...  
C... "I... S... T... I... C... S...  
G... F... P... F... P...;

I D... 9 G... B... I... F... CSR R... C... 12  
I... F... S... R... C... TOT... F... P...  
CSR...

## Pa...e a, d, b d a e

F... P... I 2016,  
F...


F... P... P... P... F... P... S... S... C...  
I S... J... C... T... P... F... P...  
P... P... S... P... D... P... S...  
P... "T... S..."

## C...e...-g...e...a...-ga...a

I 2016, F... P... G... 35...  
...

I 2016, G... 100...  
...

T... 90...  
...



C... 35



T... 90

## Tree P, b, c

F P I ... ;  
T F P I, C F P I, ( L I),  
I 2016, F P I ;  
F P I G C " ;  
F P I G F  
P B P R D  
I 2016, F P I S I ;  
G ;  
F P I I 2016, 250,471  
P I S G

## Rea ... reg . e, e

F P I "2016 P I C L O D  
C " "2016 M S I D O C  
C B D C " M C  
100 30  
C ;  
F P I Q D M C "2016  
P I Q D C " 20 30  
F P I 20 I  
P  
F P I A M R P A L ,  
A M R P P  
T C " M I I "13 F P I  
P I I M I I T  
S CPPCC S CPPCC  
P "D P H I "  
S ;  
T D R D CFDA "C T S C  
P M D "E C T S C M D "  
B ,  
A  
T R E G L B B I , R&D  
P H S F P I  
S ;  
H P S T P S C T  
H P I C A A  
N F S "D T A " C A A  
C A A ;  
T S  
G H P S B C  
G H

F P E H B C H A  
SASAC,

### Employee

P E  
T F P  
F P T G

T C T

I 2016, F P 500

( )

A T G H  
G 2016;

T N F C N 12 C D  
2016.

S F P

C F C

C ;

F M " B "E  
C ; APP C QR

( ) E QR

S S G

### Satisfaction & Feedback

T 2016 CSR 2015. I  
2015, G 200 A

GE, H G B T C F

P CSR





F  
B008414999786%;  
95%









# Keşif amaçlı deneysel Farklı Pratik



## Referans bende eğilim



## Her bir deney için elde edilen





## Overall Performance

Item	2016, FY	2015, FY	2016, H1	2015, H1
Operating Profit	RMB14,628.82	RMB10,259.54	RMB3,571.55	RMB2,805.84
Operating Profit Margin	16.02%	14.83%	5.92%	14.05%
Operating Profit per Share	RMB2,092.78	RMB2,092.78	26.36%	26.36%



## Product Development

**R&D Investment**

For FY 2016, R&D investment was RMB14,628.82 million, an increase of 42.5% from RMB10,259.54 million in FY 2015. For H1 2016, R&D investment was RMB3,571.55 million, an increase of 26.9% from RMB2,805.84 million in H1 2015. R&D investment accounted for 16.02% of operating profit in FY 2016, up from 14.83% in FY 2015. In H1 2016, R&D investment accounted for 5.92% of operating profit, up from 14.05% in H1 2015. R&D investment per share was RMB2,092.78 in FY 2016, up from RMB2,092.78 in FY 2015. In H1 2016, R&D investment per share was 26.36%, up from 26.36% in H1 2015.

**R&D Personnel**

As of the end of FY 2016, the total number of R&D personnel was 1,234, an increase of 15% from 1,064 in FY 2015. The total number of R&D personnel in H1 2016 was 617, an increase of 12% from 549 in H1 2015.

**R&D Expenses**



For FY 2016, R&D expenses were RMB14,628.82 million, an increase of 42.5% from RMB10,259.54 million in FY 2015. For H1 2016, R&D expenses were RMB3,571.55 million, an increase of 26.9% from RMB2,805.84 million in H1 2015. R&D expenses accounted for 16.02% of operating profit in FY 2016, up from 14.83% in FY 2015. In H1 2016, R&D expenses accounted for 5.92% of operating profit, up from 14.05% in H1 2015. R&D expenses per share was RMB2,092.78 in FY 2016, up from RMB2,092.78 in FY 2015. In H1 2016, R&D expenses per share was 26.36%, up from 26.36% in H1 2015.

**R&D Management**

We have established a R&D management system (SOP) and a R&D management system (GCP) to ensure the quality and efficiency of R&D activities.


## R&D Performance

R&D Investment of Fosun Pharma Group for 2012-2016 (RMB1,000,000)




2016, R&D investment reached RMB1,106 million, an increase of 33.23% compared to 2015.


## R&D Investment




## R&D Pipeline



## Patent Application



## Patent Application Success Rate



T A M P

T	A	M	P
	P	INN	I
	A	R P G	F B
	S L	P I	F II
M	S P	G T	F II
	B	R E H	F
	L T	F	F
	N/A	C	F
	A	M C A	T
	D E	A D E	T
	K	D	T
C	B T	H I	T
	B T	T	F
	B	P	H
	M	C	F
B	A D J	D C B	T ( )
	Q	O T F	T
A	ARTES@PLA	A P	M M
	ARTES@N		
	C C	C S	T
	S D L K		I
	N N K	E P H R T	F
	N/A	R	I
A	Q S S G S L	P S S	F
	E B	S	I

56-0.349-00A)(.T L U5) 0)-10.016E 11(( ) 0 13.228 0.421P)( 11 )IT D

# Healthcare Services

In 2016, the Healthcare Services segment generated RMB1,677.56 million, an increase of 21.67% from 2015. The segment's performance is primarily driven by the expansion of its service portfolio and the successful completion of several key projects. The segment's operating profit for 2016 was RMB1,677.56 million, compared to RMB1,386.00 million in 2015. The segment's operating profit margin was 21.67% in 2016, up from 18.17% in 2015. The segment's operating profit is primarily derived from the provision of healthcare services, including medical diagnosis, treatment, and rehabilitation. The segment's operating profit is also significantly influenced by the timing of the recognition of revenue and expenses. The segment's operating profit is expected to continue to grow in the future as the company expands its service portfolio and improves its operational efficiency.

# Medical Devices and Medical Materials

In 2016, the Medical Devices and Medical Materials segment generated RMB2,663.91 million, an increase of 18.17% from 2015. The segment's performance is primarily driven by the expansion of its product portfolio and the successful completion of several key projects. The segment's operating profit for 2016 was RMB786.21 million, an increase of 14.19% from 2015. The segment's operating profit margin was 29.52% in 2016, up from 27.28% in 2015. The segment's operating profit is primarily derived from the sale of medical devices and medical materials. The segment's operating profit is also significantly influenced by the timing of the recognition of revenue and expenses. The segment's operating profit is expected to continue to grow in the future as the company expands its product portfolio and improves its operational efficiency.

# Prace a Doba a d Re a,

2016, S.	G			
2016, S.	RMB258.388		RMB6,892	
	RMB4,647	12.99%, 20.04%	23.20%	2015.
A	2016,	S.	31	
	C.T		14,231 (	
	1,991			
	.D	R	P	S.
		13.34%		
2015	RMB246.459	.M	S.	
	RMB10,239		R	P
	17.29%		2015,	
			G	D
S	3,502.			

# Cea f a e g M&A a d e g a

2016,	G		
		G	

A  
(C)

						(RMB10,000)
		T	E	O	*	T
	7,673	2,001	7,614	847		225,356
22,936	6,345	1,519	4,962	3		200,597
20,678	4,759	1,408	4,850	285		163,190

## Weyang Ge a c H a

J 2016, G H C T  
C T  
C F

## Y G a g r a M e d c a L e e e M a g e e C a L e d e

C G L M I M  
F H N .1  
P N .1 P C F P .1  
T  
A G H  
B H  
J ( ) 0.037 ( ) -34 )10 7 ( ) 0.5 ( ) 9 ( 23 - -0.00





P



### Era ce a a age e



2016, O P Q A  
 C F P 13  
 14



### I ere a e C a c a

	2015	2016
D S A /	77	58
N	358	401

F P G  
 ...  
 ...  
 ...



### I ere Q a S e C e ca

**13** API  
 ce fed b  
 cGMC

C G 13 API GMC FDA  
 SA, E, M H J H B G  
 G P 1  
 2 API (5 API),  
 HO-PQ P 1  
 H C  
 FDA SA



### Pa a e a a g

c a e a e 23 / e >23 / e

I 2016, F P G  
 ...  
 ...

ca a f ra ace ca a fac g e be



### I e c e e ce



I ere a e ca e  
 e ce e a a

a 2016, re a a

P  
 ...  
 ...

I 2016, C H  
 "E H I M  
 S "(NHFPC H N )



.T  
 .E  
 I 2016, ISO13485  
 CE  
 .A  
 P  
 .A

S	P	S	F	P	G	D	F	A	R
H_P				0				16	P
A_P				2				14	P
A				3				0	P
F				7				5	P
H_P				5				33	P
B				1				22	P
T				2				15	P
P				0				39	P
C_B				5				1	P
J				4				0	P
S				3				1	P
S_S				1				0	P
D_P				2				13	P
E_P				2				60	P
G_P				9				39	P
P				5				136	P
C_P				2				7	P
H_P				0				0	P
R_P				4				0	P
S_H				2				0	P
T				58				401	P

S	C	R	I	M	D	S	F	P	G
E									
P	F	2016	FDA						
P	A	2016	FDA						
C	M	2016	FDA						
G	M	2016	HO						
G	M	2016							
H	M	12 16J	2016	DN					
S	T	24 26A	2016	JR					
L	T	30 31M	2016	JR					



## Medical device recalls

In 2016, we had no medical device recalls. We are committed to ensuring the safety and efficacy of our medical devices through rigorous testing and quality control. We have implemented a robust recall process to quickly address any potential issues and ensure patient safety.

## Certificate of Good Manufacturing Practice (cGMP) Certifications

In 2016, we achieved 13 API cGMP Certifications. These certifications are a testament to our commitment to quality and regulatory compliance. We have also received 2 API HO-PQC certifications and 1 FDA certification. Our certifications are issued by the FDA, MHRA, and other regulatory bodies, ensuring that our products meet the highest standards of quality and safety.

Percentage of products meeting quality standards

100%


0



13 API cGMP Certifications

1 HO-PQC Certification  
2 API HO-PQC Certifications (5 API)  
1 FDA Certification

## Organizational Structure



## Human Resources

Department	Number of Employees	Number of Employees	Percentage
Marketing & Sales	5	5	100%
Finance	2	2	100%
Operations	0	0	
Development	0	0	

## Marketing & Sales

Marketing & Sales is responsible for promoting the company's products and services. In 2016, the department achieved a significant milestone by reaching 72% of its target. The team is currently working on several key initiatives to further expand the company's market reach.

Marketing & Sales is currently working on several key initiatives to further expand the company's market reach. The team is currently working on several key initiatives to further expand the company's market reach.

### Product Development

Product Development is responsible for creating and improving the company's products. In 2016, the department achieved a significant milestone by reaching 80% of its target. The team is currently working on several key initiatives to further improve the quality and performance of the company's products.

Product Development is currently working on several key initiatives to further improve the quality and performance of the company's products. The team is currently working on several key initiatives to further improve the quality and performance of the company's products.



100%

100%

8

0

In 2016, the company achieved a significant milestone by reaching 100% of its target. The team is currently working on several key initiatives to further improve the quality and performance of the company's products.

# Marketing & Sales

In 2016, we continued to invest in our sales and marketing capabilities, focusing on digital marketing and social media. We have implemented a new CRM system to improve our customer relationship management. Our sales team has achieved significant growth, with a 15% increase in sales volume compared to 2015. We have also expanded our distribution network, reaching new markets and increasing our market share. Our marketing efforts have resulted in a 20% increase in brand awareness and a 10% increase in customer loyalty. We have also invested in training and development for our sales and marketing teams, ensuring they are equipped with the latest skills and knowledge. Our sales and marketing performance has been a key driver of our overall business success in 2016.



Customer Support

>40,000


Hours of Support

>5,100

Open Tickets

>2,000

Marketing & Sales Process



# Q a Safe T a g

I  
 G  
 .K  
 GMP

I 2016, G A  
 23

I R S A  
 M D F  
 P G

M F P G  
 .S  
 .S  
 .S

## Q T M P S F P G 2016

	I P	G P	B A P	E P	D P	
A ( / )	15.6	26.0	29.3	24.6	27.4	18.3

N :

1.D B B

2.D P P

---



---



---



---



---

# S e M a n a g e e

S  
 I 2016,  
 P G S M F P G H S B G (T),  
 M ITP M M F P G (T), M N  
 P C P M S F P G (T), M M  
 T D P P S F P G (G) C L (R), T  
 D P T P F P T D  
 P T M S T T D I  
 P F P

G  
 S 2016  
 C G  
 M F P T G  
 I 2016, F P 447 557 110  
 F T 447 110  
 I 2016, F P

F P  
 I 2016, F P 2015  
 ( / ), 671  
 F P  
 A F P ( )

I G  
 P  
 D T G  
 S  
 F P

M F  
 T M T F P  
 14

I 2016, F P


557

447

110

F P

671



S \_ M \_ \_ M P \_ \_ S \_ \_ F P \_ G \_ 2016

S \_ \_ G \_ P \_ \_ \_ B \_ \_ A \_ P \_ \_ E P \_ \_ \_ P \_ \_

---



---



---



---



---




---



---

O T P F P \_ \_ S \_ \_







A ...  
F ... P ... G

95.39%

.T ... ( ... )  
" ... " ...  
.D 2016,  
.M ...  
17 ...  
A ... ( ... )  
92%,  
95.39%. C ... H ...  
" (N ... H ... F ... P ... C ... JKB),  
G ... P ... "  
C ... ) 2016.

C ... S ... S ... M ... S ... S ... F ... P ... G


S ...	J... C ... H ...	G ... H ...	... H ...	C ... H ...	G ...
S ...	97.8%	95%	95%	96.8%	92.32%


M ... F ... P ... G

S ...	G ... H ...	C ... H ...	... H ...	J... C ... H ...	G ...
M ...	9	5	3	0	0

N :T ...

R ... P ... A ... S ... P ... C ... H ... (G ... P ... )







O C L O U D , F P I L L O S I T Y



I... e e f be e  
 e e e

" F P... F P... EHS  
 S P... F P... E... H..."



# Implementation of EHS Program

## Management, Measurement, System Operation & Monitoring

Fosun Pharma Group has implemented the EHS management system in accordance with the requirements of ISO 14001 and OHSAS 18001, and has established a comprehensive EHS management system covering the entire Fosun Pharma Group.



### Management

At the "Moment of the Brand" section of the 2016 Fosun Pharma annual meeting, the senior management members of Fosun Pharma (including the Chairman and President) signed the commitment for quality and EHS, and released the commitment to the stakeholders of Fosun Pharma that Fosun Pharma will create better and happier life for the people through innovation.



### Measurement System operation & Monitoring

To continue implement the guidelines and basic requirements described in Fosun Pharma The Environment, Health and Safety (EHS) handbook, including EHS seminars, EHS technical & awareness trainings, risk identification and assessment, cross audit, routine & non-routine inspection, EHS concern reported-out, and EHS red/yellow flagged issues. It's the first time to highlight and enhance the reporting-out requirement for EHS accident/incident/potential risks. The relating management team may finally be held accountable for their any violation to the incident report procedure, which aims to enhance the EHS management and control level and to minimize the EHS risks by strengthening the EHS management in a top-down approach.



### Group Internal Audit

The EHS audit scope within the subsidiary, with the five more subsidiaries, two more Business Units being involved in Y2016. Two major business units (medical diagnosis and medical devices) of Fosun Pharma Group for the first time, which marked the extended application of EHS management system on Fosun Pharma Group's subsidiaries in medium and smaller segments, and paved the way for intensive implementation of EHS system in Fosun Pharma Group.



### External Certification

The subsidiaries voluntarily took further steps to carry out external third party certification/assessment. By the end of Y2016, totally 10 subsidiaries of the Group received third party certifications of ISO 14001 and/or OSHAS 18001, and 21 subsidiaries passed the third party assessment on safety standardization of the PRC, representing an increase of 1 and 8 subsidiaries, respectively, as compared with last year.

Table 1: EHS System Implementation Status of Fosun Pharma Group in 2016

Company Name	System	Standard	Year	Company Name	System	Standard	Year
B. J. P. S. F.	ISO14001, OHSAS18001, CI	III S	2016	E. P. J.	ISO14001, OHSAS18001, CI	III S	2016
J. P. S.	ISO14001, OHSAS18001, CI	III S	2016	C. P. J.	ISO14001, OHSAS18001, CI	II S	2016
P. J. S.	ISO14001, OHSAS18001, CI	II S	2016	P. J. S.	ISO14001, OHSAS18001, CI	II S	2016
S. S. F.	ISO14001, OHSAS18001, CI	III S	2016	H. P. J.	ISO14001, OHSAS18001, CI	II S	2016
F. J. S.	ISO14001, OHSAS18001, CI	III S	2016	J. C. H.	ISO14001, CI	III S	2016
C. B. J.	T. II S	2016		R. P. J.	T. III S	2016	
D. P. J.	T. III S	2016		G. H. J.	T. III S	2016	
A.	T. III S	2016		L. M. M.	T. II S	2016	
G. P. J.	T. III S	2016		F. B.	T. II S	2016	
H. P. J.	T. II S	2016		H. a. Med ca	T. III Safe. S. a. da. d. a.	2016	
S. E. T.	T. III S	2016					

## Case: The application of BBS WeChat mobile app

The "EHS Health and Safety Risk Assessment" system is a mobile application developed by Fosun Pharma Group. It is designed to help employees identify and report safety risks in real-time. The application is available on both iOS and Android platforms. It provides a user-friendly interface for reporting risks, including text, photos, and videos. The system also includes a risk assessment tool that helps users evaluate the severity of the reported risks. The application is currently being used by a large number of employees across the Fosun Pharma Group, and it has been highly praised for its effectiveness in improving safety management.



Figure 1: Screenshot of the BBS WeChat mobile app interface

# Environment, Health and Safety (EHS) Policy

## EHS

For the purpose of this policy, the following definitions apply:

Environment: The natural and built environment, including air, water, soil, and the natural world.

Health: The physical and mental well-being of employees and the community.

Safety: The prevention of accidents, injuries, and occupational diseases.



EHS



1. Commitment to the highest standards of Environment, Health and Safety (EHS) performance.

EHS



2. Commitment to the highest standards of environmental protection and management.



3. Commitment to the highest standards of occupational health and safety.



4. Commitment to the highest standards of communication and transparency.



5. Commitment to the highest standards of innovation and improvement in EHS performance.

EHS  
EHS

EHS



6. Commitment to the highest standards of environmental protection and management.

EHS

EHS

For the purpose of this policy, the following definitions apply: Environment: The natural and built environment, including air, water, soil, and the natural world.

EHS

EHS



## Fig C

- 1) Total assets: 8,769,376 (2016) vs 52,439 (2015.T) vs 139,000 (2015.I). Change from 2015.T to 2016: 1.61%. Change from 2015.I to 2016: 24.1%. RMB10,000, 1.9. D 2016, S 396,000.
- 2) E 478,175,186 (2016) vs 53,707,564 (2015.I). Change from 2015.I to 2016: 12.7%. D P, F, L, T, S, S, G 2016.
- 3) O 185,690,272 (2016) vs 12,276,649 (2015.O). Change from 2015.O to 2016: 7.1%. 126.93 /

## C E / C F P G

	T	T	E	T	O	E	
	( <sup>3</sup> /)	( / )	( / )	( / )	( / )	( / )	( <sup>3</sup> /RMB10,000)
2012	6,175,823	249,387,502		79,928,627			
2013	7,777,884	365,006,317	44,859,276	120,177,461	165,036,737		
2014	8,377,364	421,765,752	51,835,011	122,713,255	174,548,266	171.56	8.23
2015	8,716,937	424,467,622	52,209,518	121,204,106	173,413,623	157.01	7.89
2016	8,769,376	478,175,186	58,815,548	126,874,724	185,690,272	126.93	5.99

Item	2016 (RMB '000)	2015 (RMB '000)	2014 (RMB '000)	2013 (RMB '000)
Basic	204,303	9,100,000	1,119,300	2,431,044
Joint	114,315	8,030,000	987,690	2,454,958
Product	92,698	6,385,400	785,404	1,051,983
Construction	59,910	7,021,980	863,704	1,102,893
Finance	8,960	1,353,675	166,502	512,647
Service	24,310	333,900	41,070	102,515
Direct Product	391,608	9,358,414	1,151,085	8,040,063
A	61,388	5,118,909	629,626	1,214,438
Government Product	720,702	30,072,609	3,698,931	6,550,133
Sales	4,603,314	292,250,000	35,946,750	87,430,320
Hospital Product	39,259	2,634,503	324,044	451,782
Academic Product	123,433	7,078,740	870,685	2,818,551
Hospital Product	45,236	1,021,655	125,664	596,698
Education Product	285,663	16,096,174	1,979,829	3,024,794
Construction Product	123,820	6,018,550	740,282	1,010,622
Product	348,581	29,640,192	3,645,744	3,808,225
Technology	12,952	29,119	3,582	265,678
Technology	109,823	513,300	63,136	272,628
Science and Health	12,166	2,885,625	354,932	918,496
Science and Technology Product	972	5,768,580	709,535	4,941
Construction Research Institute	42,387	1,247,716	153,469	64,617
Research Product	12,543	2,416,970	297,287	422,558
Finance Product	2,857	220,420	27,112	
Government Health	221,800	2,789,010	343,048	226,003
Health	132,141	4,555,651	560,345	29,619
Construction Health	511,000	11,930,000	1,467,390	1,187,084
Joint Construction Health	185,316	1,666,000	204,918	95,700
Government Health	136,888	1,942,106	238,879	1,924
Construction Management	820	246,443	30,312	531
Basic	6,531	804,042	98,897	6,938
Labor Management	5,613	1,858,608	228,609	21,369
Finance	935	309,768	38,101	122
Other	1,044	158,182	19,456	
Finance Management Service	561	157,114	19,325	4,900
Health Management	34,500	1,218,783	149,910	36,813
Construction (Basic)	335	47,717	5,869	
Construction Service	180	20,151	2,479	6,083
Science and Technology	36,885	2,884,972	354,852	390,632
Labor and Technology	50,000	2,060,000	253,380	316,422
Academic	3,623	925,208	113,801	
Construction Technology	4	5,000	615	

B I E C M S F P I G 2016


N	E	N	L	C	S	R	D	G	F
( )	( )	( )	( )	( )	( )	( )	(L)	(L)	( )
B	9,100,000		15,600		27,112,000		200	74,300	
J	8,030,000		8,400		28,458,000				
P	6,385,400	5,338			11,997,000			15,080	
C B	7,021,980				12,629,320		5,301	12,569	
F	1,353,675	353,787	2,313				180	35,700	
S	333,900		1,800		955,000			16,500	
D P	9,358,414	1,283,596				8,855,000	350	6,898	
A	5,118,909		2,890		13,867,860			18,991	
G P	30,072,609	805,820				7,649,000	1,078	12,614	
S S	292,250,000					122,400,000			
H P	2,634,503		2,400		4,983,300		400	18,650	
A P	7,078,740		10,617	5,009,029			139,324	51,484	
H P	1,021,655		5,550				21,849	28,081	371,530
E P	16,096,174		831		34,829,000		4,008	29,705	
C P	6,018,550	41,846			11,135,340				
P	29,640,192	2,835,488					5,780	28,233	
T	29,119				2,979,000			9,600	
T	513,300	109,820					76,393	31,649	
S T H	2,885,625						750,000	5,636	
S T P	5,768,580							4,651	
C R I	1,247,716	36,020						15,730	
R P	2,416,970				4,920,300		400	100	
F P	220,420								
G H	2,789,010	156,250					6,569	9,600	
H	4,555,651							8,289	14,569
C H	11,930,000	854,000					14,924	31,164	
J C H	1,666,000	48,985					5,900	22,000	
G H	1,942,106						10	1,800	
C M	246,443							500	
B	804,042							6,531	
L M M	1,858,608						100	20,000	
F B	309,768						100		
	158,182								
F M S	157,114						360	4,200	
H M	1,218,783						12,820	19,970	
C (B)	47,717								
C S	20,151						5,000		
S T	2,884,972						316,000	5,800	
L T	2,060,000	237,911							
A	925,208								
C T	5,000								




## Uraian a.d.e. secara

Untuk tahun 2016, konsumsi air per kapita (G) adalah 8,769,376 liter (L), yang merupakan peningkatan 6,42% dibandingkan dengan tahun 2015. Total konsumsi air per kapita (G) untuk tahun 2016 adalah 563,081 liter (L), yang merupakan peningkatan 6,42% dibandingkan dengan tahun 2015.

6.42%



## Walaupun demikian



2016

No	Nama Perusahaan	Volume (Liter)	Total (Liter)
1	PT. SIAKAPALKA	700	700
2	PT. SIAKAPALKA (R)	31,800	31,800
3	PT. SIAKAPALKA (C)	1,300	1,300
4	PT. SIAKAPALKA (A)	2,500	2,500
5	PT. SIAKAPALKA (S)	30,000	30,000
6	PT. SIAKAPALKA (R)	450	450
7	PT. SIAKAPALKA (S)	29,000	29,000
8	PT. SIAKAPALKA (S)	396,000	396,000
9	PT. SIAKAPALKA (B)	3,552	3,552
10	PT. SIAKAPALKA (R) EDI	11,550	11,550
11	PT. SIAKAPALKA (D)	6,000	6,000
12	PT. SIAKAPALKA (C)	960	960
13	PT. SIAKAPALKA (R)	32,984	32,984
14	PT. SIAKAPALKA (R)	300	300
15	PT. SIAKAPALKA (M)	120	120
16	PT. SIAKAPALKA (M)	100	100
17	PT. SIAKAPALKA (M)	7,415	7,415
18	PT. SIAKAPALKA (S)	30	30



T... F... G... 2016

S	1.R	C	( )	8,000	6,000	-	-
		C		1,030	859	-	-
	2.A	S		1,030	859	-	-
		E	( )	25.4	25.4	25.4	100%
		A	( )	416	247	-	-
	3.P	M	(LDPE)	2,000	660	-	-
		C		0	247	247	100%
		H	( )	1,000	500	-	-
		M		98,500	86,600	-	-
		L		70,000	62,000	-	-
D P	1.R	L		42,720	42,720	-	-
		T		67,520	67,520	45,000	66.6%
		D		2,000	1,529	-	-
		L		20,300	17,490	-	-
	2.A	C		16,375	11,687	-	-
		M		2,030	1,450.5	-	-
		S		3,503	3,703	-	-
	3.P	P	(0,000)	1.43	1.42	0.14	9.6%
		P	(0,000)	18.46	15.87	0.3	1.9%
	A	1.R					



T... F P... G ... 2016

N...	T...	N...	T...	A...	R...	R...
	1.R	P... (0,000...)	474.94	474.75	-	-
		S (...)	1,749	1,657	-	-
		A (...)	38	41	-	-
T...	2.A	R... (L)	3,000	850	-	-
		P... (...)	22	22.9	-	-
		A... (...)	11.8	10.15	10.15	100%
	1.R	G...	N...	N...		
S...	2.A	A...	N...	N...		
H...	3.P	R...	N...	N...		
	1.R	B...	15	15	-	-
		T...	15	15	-	-
		C... M...	165	165	-	-
	2.A	S...	50-			
S T						
P...						





Water and Sewerage

Total 490 2016, 0.5% 2015.T NH3-N 60.55, 8.1% 2015.F P/G



0 A

D G

D. F P/G 2016

N	T D	COD	NH3-N				D
( )	( )	( )	( )	( / )	( / )	( / )	( / )
B	163,450	23.864	0.670				P
J	91,000	9.282	0.002				P
P	18,584	0.855	0.003				P
C B	53,919	1.941	0.511				T P
F	7,200	0.504	0.017				P
S	21,000	0.000	0.000	N			H T P
D P	313,286.4	18.703	2.115				D D C T P
A	52,180	3.340	0.000				P
G P	576,562	40.359	0.000				P
S S	3,722,626	279.197	44.672				D R
H P	36,586	1.463	0.013				P
A P	80,000	9.600	0.000				P
H P	36,188	0.984	0.090				P
E P	197,104	16.872	0.487				P
G P	80,937	3.262	1.531				S F D C L
P	96,417	3.754	0.329				P
T	12,952.26	2.590	0.000				Q T C
T	93,349.65	0.000	0.000				P T P S N D
S H	6,083	0.274	0.091				T C
S T P	972	0.292	0.010				P
C R	33,909.6	3.221	0.458				P
R P	12,150	3.038	0.122				P
F P	2,285.6	0.217	0.031				P
G H	221,800	12.643	0.956	N			D L
H	118,926.9	3.496	0.035				C
C H	332,279	8.307	5.316				C
J C H	148,252.8	12.572	1.097				P
G H	136,194	9.806	1.634				P
C M	656	0.033	0.005	N			P
B	6,531	0.000	0.000	N			P
L M M	5,052	0.808	0.019				P
F B	842	0.135	0.003				P
	1,043.57	0.000	0.000	N			P
F M S	505	0.000	0.000	N			P
H M	27,600	2.208	0.276				D
C (B)	335	0.000	0.000	N			D
C S	180	0.000	0.000	N			D
S T	33,196.5	16.233	0.050	N			P
L T	40,000	0.000	0.000				P
C T	4	0.000	0.000	N/A	N/A	N/A	

## Case: Waste Water Treatment and Sewerage Schemes in Ahmedabad

In 2005, RMB5.11 was allocated for the construction of a 600<sup>3</sup>/d capacity Sewerage Treatment Plant (STP) in Ahmedabad. The STP was designed to treat the effluent from the existing STP and the effluent from the existing STP. The STP was designed to treat the effluent from the existing STP and the effluent from the existing STP. The STP was designed to treat the effluent from the existing STP and the effluent from the existing STP.

## Case: Upgrade of Waste Water Treatment and Sewerage Schemes in Ahmedabad

The STP was upgraded in 2016, to increase its capacity to 1000<sup>3</sup>/d. The upgrade included the installation of new aeration tanks, secondary clarifiers, and sludge settling tanks. The STP was designed to treat the effluent from the existing STP and the effluent from the existing STP. The STP was designed to treat the effluent from the existing STP and the effluent from the existing STP.



A. e

A. E... F P... G... 2016

N...	N...	S...	P...	N...	T...
( / )	( / )	( / )	( / )	( / )	
J...	0.000	0.001	0.000	0.12	A...;B...F...
P...	0.000	0.010	0.130	0.07	
F...	3.359	0.611	0.370	0.00	F...
D... P...	0.002	0.001	0.000	0.00	D...
G... P...	32.863	23.886	8.817	0.00	D...
S... S...	419.839	441.936	6.187	0.00	D... + ...
A... P...	0.000	15.747	1.030	0.00	N/A
H... P...	3.384	2.269	1.086	0.00	E...
E... P...	0.869	0.000	0.185	0.00	E... 35- ...
G... P...	0.000	0.000	0.000	1.34	M... + ... 20...
P...	4.007	0.180	0.604	0.00	D...
S... T... P...	0.000	0.000	0.000	0.01	D...
C... R... I...	0.03	0.038	0.013	-	D...
R... P...	0.000	0.000	0.000	0.55	O... " ... + ... + ..."
C... H...	1.414	0.000	0.007	0.00	1.1... 2.0...
L... M... M...	0.002	0.000	0.000	0.00	E...
S... T...	0.010	0.014	0.014	0.00	N/A

N :T ...

 **Case: B... P... ec f "C a- -Ga E ec... c... C... e..."**

T... T... A... " ... ". D... 2016, D... P..., ... F... L... T...

 **Case: T... f... a... ec f... a... ega c... ec ed... fca...**

G... P... RMB2... (OC) ... T... 30...

**S, d, a e a, g e e,**

I 2016, F P G 80,848.14 .D P ,  
F L T 3,158  
( ) 909

I 2016, G  
E

Detailed Financial Performance 2016


Name	Total								
	T	H	I	R	L	O	D		
H	229.67	146	0	83.67	0	83.67	0	0	H
C	738	535	0	203	0	203	0	0	H
J	23.87	11.91	11.91	0.04	0	0.04	0	0	H
G	192	75	0	117	0	0	0	117	H
M	0.67	0.63	0.02	0.02	0	0	0	0.02	H
B	15.3	9.6	0	5.7	0	2.5	0	3.3	H
M	25.3	12	12	1.3	0	1.3	0	0	H
B	3.37	2.08	1.08	0.21	0	0.21	0	0	H
	0.84	0.75	0	0.09	0	0.09	0	0	H
M	1.51	1.5	0.01	0	0	0	0	0	C
M	63	60	3	0	0	0	0	0	S
(B)	13	13	0	0	0	0	0	0	C
S	0.5	0.5	0	0	0	0	0	0	C
T	15	5	10	0	0	0	0	0	C
T	78	50	28	0	0	0	0	0	C
T	0.08	0.08	0	0	0	0	0	0	C

Financial Performance 2016

Name	E		E	
	P	A (RMB10,000)	P	A (RMB10,000)
O		9.30	D	35.20
T		519.20	O	28.50
C		45.00	O	42.00
B	T	0.35	M	29.36
F	E	22.90	O	17.75
S	A	5.00	T	1.00
D	T	20.00	E	100.00
A	E	1.00		13.49
G	T	206.00		156.00
S	R	218.00	E	83.00
H	E	1.21	S	7.14

Operating income

Operating income	2016	2015
	RMB33.46	RMB20.27
	(RMB13.19)	



Operating income 2016

Name	E		E	
	P	A (RMB10,000)	P	A (RMB10,000)
Advertising			Direct advertising	22.00
Home products			Electronics	14.00
Electronics	Television	35.10	Home products	168.10
Home products	Electronics	10.40	Home products	19.50
Consumer products	Television	136.59	Electronics	192.90
Television	Direct advertising	5.31	Direct advertising	1.11
Television	Advertising	6.12		
Service			Direct advertising	27.00
Service	Marketing	0.75	Direct advertising	5.20
Consumer products	Research and development	2.00	Direct advertising	9.84
Research and development		622.00	Electronics	145.00
Service			Television	3.50
Global home products	China	12.00	Other	40.00
Home products			Other	1.48
China home products	Research and development	116.00	Other	103.80
Japan consumer products	Global	6.00	Other	0.60
Global home products			Electronics	37.29
China marketing	Electronics	0.50	Electronics	0.88
Latin America			Service	7.00
Finance			Service	0.80
Finance marketing			Other	6.00
Home marketing	Direct advertising	2.40	Other	1.50
China (B...)	Product	4.39	Product	0.45
Service	Television	3.00	Electronics	3.00
Latin America			Electronics	8.05
China	Television		Electronics	3.00

# Gee, S. Cra

I 2016, F P "G F ". F P G C C



# Acțiunea dată a re cuceră ge

## Eficienta energetică

În 2016, G  
G

A T G C 750,000 \* (CO2) G

În 2016, G C H J O H  
( ). I

F P F

M F P G  
C S

18° F E OA 26°  
O

## Ca e: Ne c ced a v e a e e

T A  
( ). C H J G H  
120,000 416,000  
998



## Ca e: T a f a f cre ca v age a ea

T  
În 2016, R  
A E  
(7.7 / 11 ( 0.5 ( ) 0.5 ( ) 0.6 ) -4 ) -4 ( 1)6.

I 2016, F P G  
 .A  
 S  
 A 2016,9 F P G  
 F 2016,F P G EHS  
 ( )  
 T  
 F P G



## Occ a a rea a d afe


F P G  
 I 2016, F P  
 I 2016 ,F P 0 ,703

### Safe


F P ( ) T EHS  
 GB6441-86 <T S C I A F I  
 E E > OSHA .L  
 ( )

I 2016, 20 0.044 (8 ) ,0.072 (13 )  
 ,0.116 (21 ) ( ) ,0.21 (38 )  
 C 2015, 69.6%,  
 81.7%, 72.7%,  
 60.7%. A

F P  
 F P (PSM) API  
 A B 2016, 0



A 2016



A 2016





S I F P G 2016

N	T	T	I					I				IH	D	LTC	
			M	S	N	N	N	200,000	F	L	R				L
B	779	1,607,070	0	0	1	0	1	0.12	0.00	1	3	0.12	0.37	0	105
J	169	344,110	0	0	0	0	0	0.00	0.00	0	0	0.00	0.00	0	0
P	306	708,990	0	0	0	0	0	0.00	0.00	0	0	0.00	0.00	0	0
C B	157	375,303	0	0	0	1	1	0.53	0.00	1	2	0.53	1.07	0	40
F	210	443,520	0	0	0	0	0	0.00	0.00	0	0	0.00	0.00	0	0
S	98	250,880	0	0	0	0	0	0.00	0.00	0	0	0.00	0.00	0	0
D P	943	1,968,984	0	0	1	1	2	0.20	0.00	2	3	0.20	0.30	0	212
A	301	660,030	0	0	0	0	0	0.00	0.00	0	1	0.00	0.30	0	0
G P	1,155	2,310,000	0	0	0	2	2	0.17	0.00	2	3	0.17	0.26	0	84
S S	1,860	4,464,000	0	0	3	0	3	0.13	0.00	3	3	0.13	0.13	0	350
H P	289	622,104	0	0	0	0	0	0.00	0.00	0	0	0.00	0.00	0	0
A P	613	1,331,090	0	0	0	0	0	0.00	0.00	0	1	0.00	0.15	0	0
H P	369	734,768	0	0	0	0	0	0.00	0.00	0	5	0.00	1.36	0	0
E P	789	1,841,777	0	0	0	2	2	0.22	0.00	2	2	0.22	0.22	0	65
C P	316	740,918	0	0	1	2	3	0.81	0.00	3	5	0.81	1.35	0	160
P	1,195	2,495,160	0	0	0	1	1	0.08	0.00	1	2	0.08	0.16	0	25
T	88	198,904	0	0	0	0	0	0.00	0.00	0	0	0.00	0.00	0	0
T	28	6,368	0	0	0	0	0	0.00	0.00	0	0	0.00	0.00	0	0
S H	292	511,704	0	0	0	0	0	0.00	0.00	0	0	0.00	0.00	0	0
S T P	95	198,360	0	0	0	0	0	0.00	0.00	0	0	0.00	0.00	0	0
C R	248	496,000	0	0	0	0	0	0.00	0.00	0	0	0.00	0.00	0	0
R P	148	340,000	0	0	0	0	0	0.00	0.00	0	0	0.00	0.00	0	0
S H F	31	80,600	0	0	0	0	0	0.00	0.00	0	0	0.00	0.00	0	0
G H	541	1,137,552	0	0	0	0	0	0.00	0.00	0	0	0.00	0.00	0	0
H	660	1,326,480	0	0	0	0	0	0.00	0.00	0	0	0.00	0.00	0	0
C H	1,700	4,406,400	0	0	1	3	4	0.18	0.00	4	6	0.18	0.27	0	270
J C H	307	677,856	0	0	0	0	0	0.00	0.00	0	0	0.00	0.00	0	0
G H	291	584,328	0	0	0	0	0	0.00	0.00	0	0	0.00	0.00	0	0
C M	19	30,818	0	0	0	0	0	0.00	0.00	0	0	0.00	0.00	0	0
F M T	151	280,000	0	0	0	0	0	0.00	0.00	0	0	0.00	0.00	0	0
L M M	321	656,588	0	0	0	0	0	0.00	0.00	0	0	0.00	0.00	0	0
F B	18	36,860	0	0	0	0	0	0.00	0.00	0	0	0.00	0.00	0	0
	67	102,137	0	0	0	0	0	0.00	0.00	0	0	0.00	0.00	0	0
F D	89	154,784	0	0	0	0	0	0.00	0.00	0	0	0.00	0.00	0	0
H M	577	1,505,970	0	0	0	0	0	0.00	0.00	0	0	0.00	0.00	0	0
C (B)	51	96,024	0	0	0	0	0	0.00	0.00	0	0	0.00	0.00	0	0
C S	126	245,844	0	0	0	0	0	0.00	0.00	0	0	0.00	0.00	0	0
S T	231	616,875	0	0	1	0	1	0.32	0.00	1	1	0.32	0.32	0	110
L T	186	428,544	0	0	0	0	0	0.00	0.00	0	0	0.00	0.00	0	0
A	213	444,744	0	0	0	0	0	0.00	0.00	0	1	0.00	0.45	0	0
C T	4	3,392	0	0	0	0	0	0.00	0.00	0	0	0.00	0.00	0	0

Note: 1. 1 minor injury incident in the headquarter of the Fosun Pharma Group was included in the lost-time cases and recordable injury cases;  
 2. (Total, Lost-time, Recordable) Rate = (Total, Lost-time, Recordable) Number \* 200,000 / Total Working Hours

### Ca e: I


R P RMB6.05 DCS, API R DCS API

### Ca e: Mecra, ca ec e e e

I F D C S 2016, F D C S T ( ) A

### Occ a a Hea r

F P ( ) D F P ( ) 2016, 2,417 100% 0.T 100%.



N  
N

A series of horizontal dotted lines for writing, spanning the width of the page.



**Environmental Performance**


Item	2016	2015
CO <sub>2</sub> emissions (t)	9,500	3,800
Water consumption (m <sup>3</sup> )	1.10	2.70
Waste (kg)	13.00	5.00
Energy consumption (kWh)	0.70	1.00

**Employee Engagement**

Employee engagement is a key driver of our success. We focus on creating a positive work environment through various initiatives such as training, development, and employee assistance programs. Our goal is to foster a culture of innovation and collaboration where employees feel valued and motivated to contribute to the company's success.

In 2016, our employee engagement score was 93,431, compared to 34,913 in 2015, representing a 215% increase. This significant improvement is a testament to our commitment to employee well-being and engagement. We will continue to invest in our workforce to ensure we remain a leader in our industry.






S	M	M
B	EHS EHS	R EHS
J	EHS	F, A, C, R EHS
F	EHS	T 7, C EHS, LOTO EHS, EHS
S	EHS	T, A EHS, B
D P	EHS	T C, C, O H, A; E GMP, A EHS; 2015
A	S	S
G P	EHS	C, S
H P	EHS	I, EHS
A P	S	S, A, C, MSDS
H P	EHS	R EHS, EHS ( ), EHS
E P	EHS	H EHS, EHS
EHS P B	EHS	1. EHS, EHS; 2. EHS; 3. EHS; 4. C; 5. I
T	S	C
T	EHS	H
S H	EHS	H
S T P	EHS	F
R C	EHS	A EHS, EHS
R P	S	H 4, 3, 2, 2, 11
S F	L	C
H	EHS	T, EHS, T 5, EHS
L M	EHS	S, EHS
F B	EHS	S, EHS
H M	EHS	T, 11 N, 2016
S T	S	R EHS, EHS
L T	EHS	F, A, C, EHS

Disclosure description: 1. The report discloses the health, safety and environmental protection quality, which is part of the working environment quality and has important effect on the Group. They include the related important performance indicators. For some key indicators which have general effect on the Group, the report has also made voluntary disclosure to some extent. 2. Six new subsidiaries, namely Wanbang Tiancheng, Wanbang Tiansheng, Fuchuang Pharma, Wenzhou Geriatrics Hospital, Zhongsheng Zhongjie and Chindex Tianjin, were included in the major subsidiaries disclosed. 3. The calculation method of total number of employees in EHS section is different from the calculation method of total number of employees in Employees section in this report, the statistical scope of number of employees for EHS section is the number of employees in service.


Data description: the statistics of the data disclosed in the above sections and each table in the EHS report are conducted in accordance with related national or local regulations, industrial standards, administrative requirements or practices formulated by subsidiaries. They are derived after reasonable verification. For the data whose validity or completeness cannot be confirmed due to various objective reasons, they are denoted with "-". For the appropriate data, they are denoted with "NA".






### Yükseklik

2016, **65.6%**




### Perakendeciler

2016, **23.92%**



### Varlık R&D




2016, **14.2%**



### Taahhütler

### Emisyonlar

50.96% 49.04%



### Trevin ve faaliyetlerin net etkisi

Cash flow net change (RMB100,000,000)

In 2016, the Group's cash payment to employees and on behalf of employees totaled RMB2,196 million,

# Sustainable Development


## Take

THE... A... G... F






Leadership Development



Ca e: E ab r e f Wa ba g U e a d  
c e ce e f ref. d c a d e a  
ç a

D G B .T  
M 2016.



B 20

T 30  
6 .T

T	S	B	
C	N		C
D	T	R	T
N	H	S	
N	M		C
S	O	C	S
T24, N	HQC		R&D
M	L	S	
S	C		
	F	P	
	O	T	
M	L	S	
P	N	GMP, GMP	
Q	T	O	P
EHS	N	E	O



**Ca e: T.a.g.P. ga e f S. Tec. Pra. 2016**

S T P... N... C...  
 N... H... S... P... F... D... G...  
 P... T... T... F... P... T...  
 T... D... E... T... FDA... CGMP... QA...  
 M... S... S... GDP... GMP...



**T... S... S T P...**

C	N	C
N... H... S...	P...	F... D... G...
P... T...	T...	F... P... T...
T... D...	E... ( )	T... FDA... CGMP... QA...
M...	S...	S... GDP... GMP...

**Ca e: Tre C. e. g. f. re F. Se. a. Ma. age e. f C. e. a. H. a. f F. Pra. a. re P. e. de**

I... F... P... F... P...  
 F... S... M... C... H... F... P... G... P...  
 T... S... N... 2016. S... G...  
 120... C... Q... C... F... P...  
 "T... C... E... F..."



S... P...  
 ...

**Ca e: Tre P. ga f "Leade. r. E. ra. ce e. f. M. dd. e. Ra. g. Ma. age." c. e. ced b. Cr. de (CML)**

T... S... M... P... F... P... G...  
 C... (CML) ... "L... E... M... -R... M...".  
 T...  
 T... P...  
 2-... T...  
 T... M...  
 E... G...  
 T...  
 M... C... (CML) ...  
 T...




# Executive Decisions

## Performance Management

The company's performance management system is designed to ensure that all employees are aligned with the organization's strategic goals and objectives. This system includes a variety of tools and processes, including goal setting, performance reviews, and feedback mechanisms. The system is designed to be fair, transparent, and effective, and to provide employees with the support and resources they need to succeed. The system is also designed to be flexible and adaptable, so that it can evolve over time as the organization's needs and goals change.

The company's performance management system is based on a set of core values and principles that guide all of our actions and decisions. These values and principles include integrity, respect, and a commitment to excellence. We believe that these values and principles are essential for creating a positive and productive work environment, and for achieving our long-term success.

The company's performance management system is also designed to be a key driver of our innovation and growth. By encouraging employees to think creatively and to take ownership of their work, we are able to foster a culture of innovation and to develop new products and services that meet the needs of our customers. We believe that this is the only way to stay ahead in a competitive market and to ensure our long-term success.



S L F P (P )

S L F P 2012 2013 2014 2015 2016

T  
8.1 ( ) 356 T 6.4 ( ) 0.5 ( ) 4.3 ( ) -23.6 ( ) 13 014 T 8485.5 0.440 10.986 0 T (2049 ) -0.452


## Employee Activities

Employee activities are important to the corporate cultural construction of Fosun Pharma Group. The Corporate Culture Working Committee ("Culture Working Committee") of Fosun Pharma fully utilizes the resources of the organization, proactively organizes and coordinates among individual departments and individual subsidiary with the support from various aspects such as the labor union, administration, human resources and branding and joins efforts in the organization of various events that help invigorate employees' cultural life and jointly proceed corporate cultural constructions.

To create an innovative culture within Fosun Pharma Group, in the first half of 2016, Fosun Pharma organized the Fosun Pharma 2016 Innovation Contest named "Xingrong e-action", which aims to identify innovative talent within the Group, uncover high quality projects and to provide support for an innovative internal environment. In view of the "Unicorn Potential Award" and "Business Innovation Award", the contest has received a total of 98 pieces of work, with more than 900 audiences voting to ultimately decide the winner.

In 2016, the labor unions of Fosun Pharma and its subsidiaries organized over 350 cultural and sports activities, including various festival caring events for employees such as Chinese New Year, Lantern Festival, International Women's Day, Children's Day, Mid-Autumn Festival, Chung Yeung Festival, Children's Day, high temperature allowance, birthday parties, employee physical examination and street market activities, as well as various employees' club activities. Fosun Pharma Group has established 12 employees' clubs which will organize various activities welcomed by the employees regularly. Meanwhile, each club proactively participates in neighborhood activities and community interaction through the





P. b. c. e. fa. e. c. b.

C. e. ce


>300 e  
V. ee. ea  
ac. e

>90 e  
P. b. c. e. fa. e. ce. a. d. n. e. a. n. c. a. a.

F. e. g. a. d. e. c.

1 P. e. c.

H.



## Service Value

In 2016, the company's service value is RMB2.99.\*

“Nursing Service” is the core of the company's service value. In 2016, the company's nursing service value is RMB2.99. The company's nursing service value is composed of the following three parts: nursing service value, nursing service value, and nursing service value.

\*N : S = ( ) /



In 2016, the company's service value is RMB2.99.

**RMB2.99**

**8.3%**

RMB 2.76 2015

## Customer Satisfaction

Customer satisfaction is the company's core value. In 2016, the company's customer satisfaction is 100%.

“Satisfaction” is the core of the company's customer satisfaction. In 2016, the company's customer satisfaction is 100%. The company's customer satisfaction is composed of the following three parts: customer satisfaction, customer satisfaction, and customer satisfaction.

“Satisfaction” is the core of the company's customer satisfaction. In 2016, the company's customer satisfaction is 100%. The company's customer satisfaction is composed of the following three parts: customer satisfaction, customer satisfaction, and customer satisfaction.

F P  
T  
I 2016, F A S D C  
T  
C  
I D OA F P F A S  
D  
A 42

### F d ca Ad a S e De a e

T  
C B D F A 2016,  
A S D C F  
C C  
I 2016, F A S  
D "A C O " T B D  
F P "A C O " T "H P M R  
E F P " C  
S F A A S S D I  
F A S D 23  
T F A S D  
M F A S D  
I 2016, F A S D  
ISO19600 C M S G

### C Cra

F P  
RMB7.97 ( I 2016, F P G )

### L c ea ed de e fec g re "FUTURE STAR" c cra c e e

F P G F P G  
P G "FUTURE STAR" 1998.F

### F F da

I 2016, F P RMB5.00 F F S B C.C.T  
L S D F "D T A " T  
"F F " T


### Ta ge ed P e A e a

F P G C



I 2016, F P  
F F

RMB5



G  
C , F P G

I 2016, F P G

RMB6.45

F P , H P RMB1,000,000 C  
A A "D T  
A " ( )

F P S L S F C P C

RMB150,000 29 (F :4  
10 ;C P :15 )

J C H F P 60  
100 RMB5,000,000.

T P C H 9

B RMB30,000 J A P 30  
D L T C " D  
M RMB50,000 J C F 207

H C .17 O 2016 P "P A D "  
A B G 2016, G P RMB60,000  
"J F A P "

H F F P C C C F D  
A C D G ,C C F I R  
G ,C C G ,C H E C C R  
I

Q D I 2016, C R I  
RMB150,000  
Q D



L P I  
M L C F  
P I  
C M

---

## Case: Joined force with Shanghai Charity Foundation to provide support to patients suffered from cancer

On 9 September, the charity day, Shanghai Charity Foundation, Fosun Foundation and Shanghai Symphony Orchestra jointly organized the charity concert of "Fosun Charity Night: Let Love Fill the New World". All the donations in the event were collected through various mobile and internet charity platforms such as Tencent, Alipay, official WeChat account of Fosun Foundation (fosunfoundation) and the official website of Shanghai Symphony Orchestra, and were donated to Shanghai Charitable Cancer Research Center to finance the doctors and scientific researchers in Shanghai who devote in cancer clinical research, so as to work out the best treatment solutions for patients suffered from cancer as soon as possible.

## Case: "Double Thousand Actions" provided timely support and care to all patients suffered from tuberculosis

On 22 March, at the promotion event of World Tuberculosis Day, Chinese Antituberculosis Association established the Chinese Anti-tuberculosis Non-profit Foundation and jointly launched the Chinese Anti-tuberculosis Non-profit Foundation - "Double Thousand Actions" assistance project for tuberculosis with Fosun Foundation and Hongqi Pharma (a subsidiary of Fosun Pharma). The "Double Thousand Actions" project will last for five years from 2016 to 2020. At least 1000 needy patients suffering from tuberculosis can be helped each year and the funding for each patient would not be less than RMB1,000. Fosun Foundation collaborates with Hongqi Pharma, a subsidiary of Fosun Pharma, to provide continuous sponsorship in the form of funding and medicine etc.

On 27 April, the 2016 National Academic Meeting of Chinese Antituberculosis Association was held in Zhuhai, Guangdong Province, and the unveiling ceremony of Chinese Anti-tuberculosis Non-profit Foundation took place at the opening ceremony.

## Case: Organization of the 2nd "Climb for Charity Competition" by Fosun Pharma with the donation allocated to Qixiang Institute of Child Development

In February, the "Climb for Charity Competition" co-organized by Fosun Foundation and Fosun Pharma was held in the headquarter building of Fosun Pharma. About 22 teams participated the activity with participants covering staff of Fosun Pharma and their families, media as well as other stakeholders. All teams completed the competition within required time. The competition finally raised a total donation amount of RMB66,000.

A meeting to allocate the donation from the "Climbing for Charity Competition" was held in April. Six project leaders of the public welfare projects which applied for the donation presented their projects. After the voting, the "Family of Children with Special Needs Rehabilitation Support Program" by Shanghai Qixiang Institute of Child Development was granted the donation.

## Case: Walking for Love— the "Shanghai United Walkathon" Volunteer Event was held again

In April 2016, the "Shanghai United Walkathon" Volunteer Event was held again. Participants and volunteers of Fosun Pharma participated the event with full enthusiasm despite of the bad weather. With the support, accompany and encouragement of teammates and the Company's volunteers, the whole 12-hour walkathon covering a total of 50 kilometers was completed successfully with full love. Fosun Pharma volunteers have participated in the "Shanghai United Walkathon" charity event for four successive years and raised over RMB300,000 for supporting the children nutrition in poor areas, rural children's reading, children with autism, quality training for migrant children as well as other sectors.

## Case: the "Bang Program": Trying the best to participate in public welfare activities

As the extension of the Company's core value of "self-improvement, teamwork, performance and contribution to society" as well as the inheritance of the public welfare mission of "trying the best to participate in public welfare activities", the "Bang Program" public welfare project team expanded the activity scope in 2016 to further cover more students in poverty and fundamental hospitals in remote areas. Through preliminary study and careful selection, in 2016, the "Bang Program" public welfare project team of Wanbang Biopharma visited Yuanyang County and Zhengzhou in Henan Province, Jingxing County in Hebei Province and Suining County in Jiangsu Province, carried out in-depth interaction with the grassroots, supported the local education and healthcare, and further improved the local educational and medical conditions and levels, which was well recognized and encouraged by the supported students in poverty areas, fundamental medical works and experts participated in the activities.



## Vee Tea

T F P 100 .S  
 2010, F P  
 F P  
 "H"  
 "S" J " S C  
 F P S C .S 2010,  
 E " J  
 F P T J  
 Q T M D S C  
 "F F L" " S C  
 T F P M D  
 D S M S ( ),  
 .G P "L  
 L C L T "T  
 30 25 T F P 17,000  
 .C H 10 L N  
 1,100 .G H "S S A"  
 3 5 .T G H

## C Service

I 2016, G 100  
 A P "H I C F  
 " O 2016. J C F  
 207 G C P S  
 J T H C C P S T H  
 C  
 B D P G  
 , N T M  
 T  
 D 90  
 T 2016, G H  
 2 3  
 5,000 M G H "T E P"  
 J C H "M -A P R"  
 "65- M T P P" C F S  
 S 65  
 "S C" .C H  
 .I 2016,  
 21 T  
 C H .A  
 C H



T 90  
**>90**



G H



O H D C  
 H R D  
 C G G

D... F P... ( ) 2016

E... P... T... R...	A... (RMB10,000)	B...
F... P... P... C... 2016F	500	RMB1,500,000 RMB1,000,000 RMB400,000
D... IT	1.5	7
B... M... S...	2	M... S...
M... & D...	30	P... D... O... R... C...
D... P... C...	60	T... S... B... J... Q... B... T... M... H...
S... F... G...	0.5	
T... F... H...	4	12
H... P... A... R... C... F... C...	18.8	H... P... F... C...
P... F... E...	2	F... B... R... C...
P... F... 7	0.427	T... 1.5 ( ) 0.5 ( ) 2H... 32.16 ( ) H... 64 ( ) 0F





# Performance Indicators

Management Information System Financial Performance

	2012	2013	2014	2015	2016
Net Profit Margin (RMB/100 million)	6.05	6.84	7.21	7.86	9.19
Basic Profit Margin (RMB/100 million)	0.80	0.90	0.92	1.07	1.21
Basic Profit Margin (RMB/100 million)	0.44	0.46	0.58	0.72	0.91
Net Profit Margin (%)	8.24%	6.22%	8.43%	9.57%	10.63%

\* Net Profit Margin = Net Profit / Total Revenue; Basic Profit Margin = Basic Profit / Total Revenue; Net Profit Margin (%) = Net Profit / Total Revenue

Management Information System Financial Performance

(RMB10,000)

	2012	2013	2014	2015	2016
Revenue	734,078	999,641	1,202,553	1,260,865	1,462,882
Operating Profit	186,598	214,062	192,501	234,662	212,540
Operating Profit	203,599	281,883	239,435	329,717	339,942
Profit Before Tax	9,725	10,436	34,047	10,666	19,511
Loss Before Tax	1,020	1,692	1,676	3,200	2,298
Operating Profit	282	1,045	85	362	974
Total Profit	212,304	290,627	271,805	337,183	357,155
Loss Before Tax	28,376	50,632	34,821	50,117	35,021
Net Profit	183,927	239,995	236,984	287,066	322,134
Net Profit	156,392	202,706	211,287	246,009	280,584
Minority Interest	27,536	37,289	25,697	41,057	41,550
Total Profit	78,900	105,080	126,821	143,449	163,136
Dividend	333	424	735	847	797

Note: Where applicable, the figures are based on the audited financial statements of the Company for the year ended December 31, 2014. The figures are based on the audited financial statements of the Company for the year ended December 31, 2015.

# S c a l d ca

---

---

---

---

---

---

---

---

# Climate Change

## Environmental Indicators (EHS) Key Figures

Indicator	2014	2015	2016
Total energy consumption (tce)	421,765,752	424,467,622	478,175,186
Energy consumption per employee (tce/employee)	51,835,011	52,209,518	58,815,548
Total greenhouse gas emissions (tCO <sub>2</sub> e)	122,713,255	121,204,106	126,874,724
Carbon footprint (tCO <sub>2</sub> e)	174,548,266	173,413,623	185,690,272
Energy consumption per unit of production (RMB10,000)	171	157	126.93
Total greenhouse gas emissions per unit of production (RMB10,000)	8.23	7.89	5.99
Carbon footprint per unit of production (RMB10,000)	3,200	3,166	3,346
Energy consumption per unit of production (RMB10,000)	1,200	2,156	2,027
Greenhouse gas emissions per unit of production (RMB10,000)	2,000	1,010	1,319
Total greenhouse gas emissions (tCO <sub>2</sub> e)	136,637	871,123	563,081
Total energy consumption (tce)	5,677,448	6,285,061	6,785,400
Total greenhouse gas emissions (tCO <sub>2</sub> e)	50,258	65,597	80,848.14
Total energy consumption (tce)	15,757	15,187	16,325
Loss of water (t)	N/A	0.424	0.116
Recycling rate (%)	N/A	0.533	0.21
Occupational safety and health incidents	14.88%	12.58%	14.89%
Health and safety incidents (RMB10,000)	2,060	4,505	3,155
Total greenhouse gas emissions (tCO <sub>2</sub> e)	N/A	71,474	93,431
Dissolved oxygen (t)	N/A	4.71	5.75
Effluent COD (t)	440	488	490
Effluent NH <sub>3</sub> -N (t)	60.94	56.00	60.55
Effluent suspended solids (t)	90	411	466
Effluent total phosphorus (t)	318	408	485
Effluent total nitrogen (t)	130	110	19



**Table fC a. Name**

F	S
J... B... G... C...L	B...
S... C... B... C...L	C... B...
H... F... P... C...L	F...
S... P... C...L	P...
J... P... C...L	J...
S... S... B...	S...
P... C...L	S...
J... H... P... C...L	H... P...
C... P... C...L	P...
S... H... P... C...L	H... P...
C... G... P... C...L	C... P...
S... S... (H...)B... E... C...L	S... S...
G... P... C...L	G... P...
S... H... P... C...L	H... P...
J... A... P... C...L	A... P...
D... A... B... C...L	A...
H... D... P... C...L	D... P...
C... P... R... I... C...L	R... I...
S... H... B... C...L	S... H...
S... S... T... P... C...L	S... T... P...
S... E... P... C...L	E... P...
S... G... C...L	S...
A... J... G... H...	J... G...
G... H... C...L	H...
S... H... C...L	H...
F... C... C... H... C...L	C... H...
S... F... L... M... M... S... C...L	L... M... M...
S... F... B... B... C...L	F... B...
B... (S...)C...L	B...

F	S
T... C... M... T... C...L	C... M...
C... (B...)I... T... C...L	C... (B...)
C... M... L...	CML
C... I... I...	C... ,CHD
A... U... L...	A...
H... M... I... C...L	H... M...
S... T... T... C...L	S... T...
S... U... B... T... E... C...L	U... T...
S... F... M... S... C... L...	F... M... S...
I... S... I...	I... S...
S... F... H... T... (G...)C...L	F... G...
L...	F...
S... F... P... C...L	P...
S... B... I...	S... B...
S... F... P... T... C...L	F... P...
D... C...L	A... T...
A... T... I	T...
L... G	L...
A... I...	A...
C... F... P... R... C...L	P... F...
C... R... P... C...L	R... P...
C... S... I... T... C... L...	C... S... T...
C... T... I... T... C... L...	C... T...
S... F... H... I... (G...)C...L	F... H... I...
S... I...	S...
G... E... C...	GE
H... T... P... C...L	T...
G... P... L...	G... P...




# Te g e

T D

GRI	A	G R I
FSC	A	F S C
EHS	A	E H S
CAPA	A	C A & P A
FDA	A	F D A
HO-PQ		H O P Q Q P Q I HO 2001, AIDS,
TO	A	T O
GMP	A	G M P
GMP	A	C G M P
OOS	A	O S S
SOP	A	S I O P
GCP	A	"G C P"
CSR	A	C S R
A	A	
CME		T O M T P G P 2014 A P A
IT	A	I T
NGO	A	N G O
CE	A	"E C" F "CE" A CE E
ISO13485		T Q M S M D I O S (ISO) .T

S



---

---

---

---

---

---

---

---

# Trend Panel E, a, a

D... PRC... T... C... F... P... "... C... F... P... G...

F... P... "... M... ,EHS... F... P...

A... F... P... A... C... F... P... "2020", S... D... G... (SDG) ... N... I... F... P... F... P... C...

C... C... F... P... "...

C... B... C... S... D... I.Q.

**G da ce a ca f a g ca e a b a e f a ce (GB 36002)**

S ↓ C P  
N -

**Dec a Ma a g P ce a d S c e (Z-1)**

-1-1	T	15-17
-1-2	P	3
-1-3	M	17
-1-4	E	23-25, 34-39
-1-5	M	23-25
-1-6	M	24-30
-1-7	M	23, 26-31
-1-8	I	27-31
-1-9	M	24, 100, 105-111
-1-10	M	19-20, 24
-1-11	M	23-25
-1-12	M	19-22

**C a d a g r (R-1)**

R-1-1	R	13, 41, 55, 80-81, 98, 101
R-1-2	R	99, 104-105
R-1-3	R	N/A
R-1-4	R	38-39
R-1-5	R	98
R-1-6	R	98-99

**Ec a c a a d c a g r (R-2)**

R-2-1	D	52-53, 104-105
R-2-2	T	38, 104

**Ba c a c e a d g r a a (R-3)**

S ↓ C  
N -

R-3-1	R	99, 104-105
R-3-2	M	92-100
R-3-3	M	98-99
R-3-4	M	98-99

**G da ce a ca f a g ca e b e f a ce (GB 36002)**

S ↓ C  
N ↓ P

**E e a d a e a (L-1)**

L-1-1	N	98-99
L-1-2	N	92-99
L-1-3	P	92-99
L-1-4	E	98-99
L-1-5	N	98-99
L-1-6	N	98-99
L-1-7	P	22, 98-99
L-1-8	T	98-99
L-1-9	M	50-51

**W a g c a d a d ca e c (L-2)**

L-2-1	T	58-60, 80-84
L-2-2	P	80-84, 100
L-2-3	R	98
L-2-4	M	98-100
L-2-5	D	38-39
L-2-6	E	38-39, 98-99
L-2-7	N	98-99
L-2-8	P	92-100
L-2-9	R	92-100
L-2-10	R	98-100
L-2-11	C	98-99

**De ca c g e a ce a dc ec ed c (L-3)**

S ↓ C  
N ↓ P

L-3-1	M	99
L-3-2	E	99, 104-105
L-3-3	M	98-99, 104-105
L-3-4	E	98-99, 104-105
L-3-5	T	21-22, 104-105

**Occ a a a e a d a f e (L-4)**

**G da ce a ca f a g ca e a b a e f a ce (GB 36002)**

S	C	P
N		
L-4-1	T	58
L-4-2	C	80-81
L-4-3	T	80
L-4-4	C	81
L-4-5	P	83-84
L-4-6	R	81-82
L-4-7	S	81
L-4-8	E	81
L-4-9	M	81
L-4-10	P	86-88
L-4-11	P	89

**De e e a d a a g f a e (L-5)**

L-5-1	P	93-97
L-5-2	M	98-99
L-5-3	P	98-99

**P e e a f a (H-1)**

H-1-1	T	58-59
H-1-2	T	71-74
H-1-3	M	71-74
H-1-4	M	71-74
H-1-5	T	71-74
H-1-6	M	71-74
H-1-7	P	75-76
H-1-8	S	75-76
H-1-9	P	60

**T r e e f a a b e e a ce (H-2)**

H-2-1	T	60-63
H-2-2	M	60-63
H-2-3	R	64-65
H-2-4	M	64

**G da ce a ca f a g ca e a b a e f a ce (GB 36002)**

S N	C	P
H-2-5	M	65
H-2-6	M	64-65, 72-73
H-2-7	M	78
H-2-8	P	58-61
H-2-9	M	57-89

**A e a a da a a a e c a e c a g e (H-3)**

H-3-1	T	79-80
H-3-2	M	79-80
H-3-3	M	79-80
H-3-4	E	60-65
H-3-5	M (GHG)	79
H-3-6	E	64-65
H-3-7	M	79-80
H-3-8	T	60-61
H-3-9	M	79
H-3-10	M	N S

**E a a e a e c a b d e e a d e e c e e f e a a a a b a (H-4)**

H-4-1	T	79
H-4-2	T	79
H-4-3	C	79
H-4-4	I	65, 79
H-4-5	M	79
H-4-6	T " " "	61-77
H-4-7	M	N E
H-4-8	T	N A
H-4-9	T	78
H-4-10	E	79

**G da ce ç a f g ç a e b e f a ce (GB 36002)**

S N	C	P
H-4-11	M	79
<b>A -c (G-1)</b>		
G-1-1	T	104-105
G-1-2	T	105
G-1-3	T	105
G-1-4	M	104-105
G-1-5	M	19
G-1-6	E	104-105
G-1-7	T	104-105
G-1-8	T	N E
G-1-9	T	104-105
G-1-10	M	104-105
<b>Fa C e (G-2)</b>		
G-2-1	T	48
G-2-2	P	N S
G-2-3	M	48
G-2-4	M	N E
G-2-5	R	98-99
<b>P f ç a e b e re a e ç a (G-3)</b>		
G-3-1	T	50
G-3-2	M	50
G-3-3	D	28
G-3-4	M	N S
G-3-5	M	N S
G-3-6	F	50
<b>Re e c f e g (G-4)</b>		
G-4-1	T	34
G-4-2		



**G da ce , ç a f , g c a e , b , e f . a ce (GB 36002)**

S N	C	P
-3-2	M	44-46

**C , e e . ce , . a dc , a , a dd e ra d , g (X-4)**

-4-1	M	47
-4-2	T	47
-4-3	T	N S
-4-4	T	48
-4-5	A	27, 48
-4-6	R	27, 48
-4-7	T	27, 47-48

**C , e l f . a , P . ec , a d P . ac (X-5)**

-5-1	R	47-48
-5-2	N	47-48
-5-3	L	47-48
-5-4	C	47-48
-5-5	N	47-48
-5-6	M	47-48
-5-7	A	22
-5-8	P	22
-5-9	P	22

**Ac , fba c e . ce (X-6)**

-6-1	I	48
-6-2	P	98
-6-3	T	47
-6-4	M	48
-6-5	F	N E

**G da ce ç a f g ca e b e f a ce (GB 36002)**

S 1	C	P
N		
-6-6	S	47, 53

**Ed ca a dA a e e (X-7)**

-7-1	C	86-88
-7-2	C	48
-7-3	C	48
-7-4	C	27
-7-5	C	27
-7-6	C	N S
-7-7	C	N S
-7-8	C	N S
-7-9	C	27
-7-10	C	N S

**S ca Pa c a (S-1)**

S-1-1	C	108
S-1-2	F	N E
S-1-3	P	105, 107
S-1-4	M	104-105
S-1-5	I	108
S-1-6	M	108

**Ed ca a dC e (S-2)**

S-2-1	F	106
S-2-2	M	106
S-2-3	A	107
S-2-4	P	J
S-2-5	A	J

**E e a d de e e (S-3)**

S-3-1	E	92
S-3-2	T	93-94
S-3-3	M	50
S-3-4	M	92

**G da ce a ç a f a g c a e a b e f a ce (GB 36002)**

S 1	C	P
S-3-5	P	105
S-3-6	A	105
S-3-7	M	105
S-3-8	M	58-59

**Tec a g de e e a dac a (S-4)**

S-4-1	I	58-59
S-4-2	L	N S
S-4-3	E	34
S-4-4	C	34
S-4-5	M	N S

**We a a d a c e c e a a (S-5)**

S-5-1	A	93
S-5-2	S	108
S-5-3	M	50
S-5-4	M	50
S-5-5	E	104-111
S-5-6	I	61-78
S-6-7	P	50
S-6-8	S	28, 108
S-6-9	P	N S
S-6-10	L	38

**He a a (S-6)**

S-6-1	M	66-80
S-6-2		108
S-6-3	M	108
S-6-4	S	64-65

## Güçlü Reklamla G4'de Başlıyoruz

Nöme	Çerçeve	Page
<b>G4 GENERAL STANDARD DISCLOSURES</b>		
<b>STRATEGİ VE ANALİZLER</b>		
G4-1*	CEO, Yönetim Kurulu ve diğer üst düzey yöneticilerin G4 konusundaki görüşleri	3
G4-2	Oran ve oranlar	3, 4, 16-17, 139
<b>ORGANİZASYONEL PROFİL</b>		
G4-3*	Oran ve oranlar	F, C, 11, 13, B, C
G4-4*	Oran ve oranlar	12, 44
G4-5*	Oran ve oranlar	B, C
G4-6*	Oran ve oranlar	12, 18
G4-7*	Oran ve oranlar	4, 11, 19
G4-8*	Oran ve oranlar	18, 35-37, 42, 44
G4-9*	Oran ve oranlar	12
G4-10*	Oran ve oranlar	92-93, 99
G4-11*	Oran ve oranlar	98
G4-12*	Oran ve oranlar	50, 78
G4-13*	Oran ve oranlar	14, 27-30, 50
G4-14*	Oran ve oranlar	46, 104-105
G4-15*	Oran ve oranlar	29-30
G4-16*	Oran ve oranlar	31
<b>IDENTIFIED MATERIAL ASPECTS AND BOUNDARIES</b>		
G4-17*	Oran ve oranlar	4, 116-117
G4-18*	Oran ve oranlar	23, 117, 139
G4-19*	Oran ve oranlar	23

\*Not: Tarihçe, faaliyet alanları ve diğer GRI4 Genel Standardı ile ilgili açıklamalar için lütfen GRI4 Genel Standardı'na bakınız. Sadece ilgili faaliyet alanları için GRI4 Genel Standardı'na başvurulmalıdır.

## Güçlü Reklamla G4'de

N	C	P
G4-20*	F	23
G4-21*	F	23
G4-22*	R	112-113
G4-23*	R	4, 12, 117

### STAKEHOLDER ENGAGEMENT

G4-24*	P	26-30
G4-25*	R	26-30
G4-26*	R	26-30
G4-27*	R	26-30

### REPORT PROFILE

G4-28*	R	4
G4-29*	D	4
G4-30*	R	4
G4-31*	P	115
G4-32*	R	4, 131-138
G4-33*	R	4, 121, 140-141

### GOVERNANCE

G4-34*	R	19-20
G4-35	R	19-20
G4-36	R	19-20
G4-37	R	23-25
G4-38	R	19-20
G4-39	R	19-20
G4-40	R	19-20

N	C	P
G4-41	R	19
G4-42	R	17, 44, 58, 104
G4-43	R	34-39, 56-91, 104
G4-44	R	19-22
G4-45	R	3, 19, 27-30
G4-46	R	19-22
G4-47	R	21, 35-38, 104
G4-48	R	19
G4-49	R	19
G4-50	R	19
G4-51	R	38-39, 59, 98
G4-52	R	19
G4-53	R	6 ( ) 0.006 T 0.757



## G bā Re g l a . e G4 l d ca . l de

N _	C	P_
G4-EC2	F	58-59
G4-EC3	C	39,98
G4-EC4	F	
<b>Ma . e P. e e . ce</b>		
G4-EC5	R	39,90
G4-EC6	P	92-93
<b>l d . ec Ec . c l ac</b>		
G4-EC7	D	105-107
G4-EC8	S	34-35
<b>P. c . e e . P. ac ce</b>		
G4-EC9	P	46-48

## ENVIRONMENTAL

<b>Ma e a</b>		
G4-EN1	M	50
G4-EN2	P	61-69
<b>E e g</b>		
G4-EN3	E	65-74
G4-EN4	E	N S
G4-EN5	E	61
G4-EN6	R	64-65
G4-EN7	R	64
<b>Wa e</b>		
G4-EN8	T	61
G4-EN9	T	N S
G4-EN10	P	65
<b>B d . e</b>		
G4-EN11	O	N S
G4-EN12	D	N S
G4-EN13	H	N S
G4-EN14	T	N S



## G 4 Re g L a e G 4 L d ca L de

N C

P

### LABOR PRACTICES AND DECENT WORK

#### E

G4-LA1	T	93, 99
G4-LA2	B	38-39, 98
G4-LA3	R	98

#### Lab /Ma age e Re a

G4-LA4	M	98
--------	---	----

#### Occ a a Hea a d Safe

G4-LA5	P	83-84
G4-LA6	T	80-83
G4-LA7		83-84
G4-LA8	H	86-88

#### T a a g a d Ed ca

G4-LA9	A	95
G4-LA10	P	93-97
G4-LA11	P	98

#### D e a d E a O

G4-LA12	C	93
---------	---	----

#### E a Re e a f W e a d Me

G4-LA13	R	38-39, 98
---------	---	-----------

#### S e A e e f Lab P ac ce

G4-LA14	P	N S
G4-LA15	S	N S E

#### Lab P ac ce G e a ce Mecra

G4-LA16	N	98
---------	---	----

### HUMAN RIGHTS

#### L e e

G4-HR1	T	N A
G4-HR2	T	93-97



## Güven ve Kalite G4'de

No	Çalışma	Ölçülebilirlik
<b>Araştırma ve Geliştirme</b>		
G4-S07	Tıbbi cihazların güvenli ve etkili olarak geliştirilmesi	N Sınırlı E
<b>Calışma</b>		
G4-S08	Medikal cihazların güvenli ve etkili olarak üretilmesi	N Sınırlı E
<b>Sağlık Hizmetleri ve Etkinlikleri</b>		
G4-S09	Profilaksiyon ve tedavi hizmetlerinin güvenli ve etkili olarak sunulması	N Sınırlı
G4-S10	Sağlık hizmetlerinin güvenli ve etkili olarak sunulması	50,78
<b>Güven ve Kalite Mecrası ve Etkinlikleri</b>		
G4-S11	Normatif ve teknik düzenlemelerin güvenli ve etkili olarak uygulanması	N Sınırlı E

## PRODUCT RESPONSIBILITY

<b>Çocuk ve Yaşlıların Güvenliği</b>		
G4-PR1	Profilaksiyon ve tedavi hizmetlerinin güvenli ve etkili olarak sunulması	N Sınırlı
G4-PR2	Tıbbi cihazların güvenli ve etkili olarak üretilmesi	N Sınırlı E
<b>Ürünlerin Güvenliği ve Etiketleme</b>		
G4-PR3	Tıbbi cihazların güvenli ve etkili olarak üretilmesi	44-46, 48
G4-PR4	Tıbbi cihazların güvenli ve etkili olarak üretilmesi	N Sınırlı E
G4-PR5	Risk management ve risk assessment süreçlerinin güvenli ve etkili olarak uygulanması	27, 31, 53
<b>Malzeme ve Cihazların Güvenliği</b>		
G4-PR6	Sağlık hizmetlerinin güvenli ve etkili olarak sunulması	N Sınırlı E
G4-PR7	Tıbbi cihazların güvenli ve etkili olarak üretilmesi	N Sınırlı E
<b>Çocukların Güvenliği</b>		
G4-PR8	Tıbbi cihazların güvenli ve etkili olarak üretilmesi	N Sınırlı E
<b>Calışma</b>		
G4-PR9	Medikal cihazların güvenli ve etkili olarak üretilmesi	N Sınırlı E




I A "S" "U" " D  
 F P 12- 50 "S" "U"  
 RMB300,000  
 I A "S" "U" " D  
 F P 12- 50 "S" "U"  
 RMB300,000  
 I A "S" "U" " D  
 F P 12- 50 "S" "U"  
 RMB300,000



## ASSURANCE STATEMENT

SGS-CSTC STANDARDS TECHNICAL SERVICES CO., LTD. SHANGHAI



The assurance team was assembled based on their knowledge, experience and qualifications for this assignment, and comprised auditors registered with Sustainability Reporting Assuror, SAI

auditor, CCAA ISO 14001 Lead Auditor, CCAA OHSAS 18001 Lead Auditor, and pharmaceutical industry experts etc.

Registered SA 8000 Lead Auditor, and pharmaceuticals

Based on the methodology described and the verification work performed, we are satisfied that the information contained within 2016 CSB Report verified is accurate, reliable and

**ASSURANCE OPINION**

On the basis of the methodology and the information and data cont

provides a fair and balanced representation of FOSUNPHARMA's sustainability activities and relevant performance in 2016. The assurance team is of the opinion that the Report can be used by the Reporting Organization's Stakeholders.

In our opinion, FOSUNPHARMA has chosen an appropriate option of assurance for this stage in their reporting.

**GLOBAL REPORTING INITIATIVE REPORTING GUIDELINES (2013) CONCLUSIONS**

**FINDINGS AND RECOMMENDATIONS**

**Stakeholder Inclusiveness**

FOSUNPHARMA had effectively identified the stakeholder. Established the channel and platform for stakeholder's communication and inclusiveness and took different ways to communication and exchange information.

**Sustainability Context**

FOSUNPHARMA had taken into account the environmental, social and economic conditions in the environmental and social conditions and combined the performance in the wide context.

**Materiality**

FOSUNPHARMA had effectively identified the stakeholder and used the stakeholder-based and process-based methods to identify the organization's significant economic, environmental and social impacts influencing the assessments and decisions of stakeholders. SGS recommended FOSUNPHARMA should strengthen involvement much more materiality topics internal enterprises management.

**Completeness**

FOSUNPHARMA's report included coverage of material aspects and significant economic, environmental and social impacts, to enable stakeholders to assess the organization's performance in the reporting period. SGS recommended include the coverage of external entities with significant impacts with information.

**Balance**

FOSUNPHARMA's report respected the balance principle with negative and positive aspects revealing. SGS recommended that the organization could describe in detail how to take measures.

**Comparability**

FOSUNPHARMA had disclosed the data of performance in 2016 compared with 2015. The data disclosed, which could help stakeholders to understand the improvement performance year by year. SGS recommended that the organization should disclose and against other organizations (for example, pharmaceutical, hospital) performance in the field.

**Accuracy**

FOSUNPHARMA's information in the report was accurate, capable to reveal more qualitative and quantitative information for stakeholders.

**Timeliness**

Assurance to know that the data and information was on a regular schedule and available in time. FOSUNPHARMA will report on a regular schedule with one year to assure the good timeliness.

**Clarity**

Report was presented different ways with words, charts, graphics and pictures, also describe with actual cases as well to ensure the stakeholders understanding easily. SGS recommended that same chapter in the reported can be refined, reduce lengthy description.

According, analyzing and disclosing methods managing and information was reliable. SGS recommended that data of dates of the data.

SGS Technical Services Co., Ltd. Shanghai Branch

Shanghai, China

**Reliability**

Through information and data collecting, controlling in CSR report, the data and info energy saving project do not use the estimate.

Signed:

For and on behalf of SGS-CSR Standard



Ben Teang  
Director, China and Hong Kong  
Certification and Business Enhancement  
28 Mar 2017

B-11/F, No.900, Yishan Road, Xuhui District  
www.cn.sgs.com



# **FOSUNPHARMA**



Follow us on WeChat

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

Building A, Fosun Hi-Tech Park, No.1289 Yishan Road, Xuhui District, Shanghai, P.R. China, 200233

Tel: +86 21 3398 7000

Fax: +86 21 33987020

For more information, please visit [www.fosunpharma.com](http://www.fosunpharma.com)